The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| QGEN | +15.75% | -1.98% | -0.4% | +2,485% |
| S&P | +14.5% | +93.32% | +14.09% | +899% |
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
Will Thermo Fisher be able to complete its deal to acquire Qiagen, or will shareholders vote it down?
The molecular diagnostics company blew past Wall Street's top- and bottom-line expectations in the first quarter for one main reason.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $533.54M | 7.5% |
| Gross Profit | $332.47M | 5.5% |
| Gross Margin | 62.31% | -1.2% |
| Market Cap | $10.41B | 13.1% |
| Market Cap / Employee | $1.81M | 0.0% |
| Employees | 5.8K | -3.4% |
| Net Income | $96.25M | 152.5% |
| EBITDA | $185.45M | 5.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $733.82M | 37.5% |
| Accounts Receivable | $385.76M | 4.5% |
| Inventory | 292.6 | -9.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $884.85M | -2.6% |
| Short Term Debt | $559.19M | 13.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 6.55% | 5.3% |
| Return On Invested Capital | 7.35% | 0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $121.25M | -5.6% |
| Operating Free Cash Flow | $161.44M | -3.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 112.89 | 123.29 | 96.19 | 28.13 | -78.52% |
| Price to Book | 2.87 | 2.77 | 2.43 | 3.05 | 19.49% |
| Price to Sales | 5.19 | 5.05 | 4.41 | 5.14 | 9.33% |
| Price to Tangible Book Value | 17.07 | 14.28 | 10.35 | 15.56 | 6.69% |
| Price to Free Cash Flow TTM | 22.03 | 19.72 | 17.48 | 21.03 | -4.63% |
| Enterprise Value to EBITDA | 59.35 | 54.44 | 54.50 | 59.19 | 8.26% |
| Free Cash Flow Yield | 4.5% | 5.1% | 5.7% | 4.8% | 4.86% |
| Return on Equity | 2.6% | 2.3% | 2.7% | 10.8% | 422.41% |
| Total Debt | $1.92B | $1.51B | $1.41B | $1.44B | 3.03% |
QGEN earnings call for the period ending September 30, 2021.
QGEN earnings call for the period ending March 31, 2021.
QGEN earnings call for the period ending December 31, 2020.
QGEN earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
